CASPOFUNGIN Labatec subst sèche 50 mg flac
7680684330018
CH-68433
J02AX04
08.06.0.
Reimbursement limitations:
CANCIDAS
Traitement de l'aspergillose invasive chez les patients réfractaires ou intolérants à d'autres traitements (l'amphotéricine B, …
1 / 3
google
Details
- Product number
- 6843301
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- Praeparatio cryodesiccata: caspofunginum 50 mg ut caspofungini diacetas, saccharum, mannitolum, acidum aceticum glaciale, natrii hydroxidum q.s. ad pH, pro vitro.
Articles (1)
Caspofungin Labatec 50 mg, Poudre pour solution à diluer pour perfusion
Puder
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
PRC
|
50.0 MG | Substance | Wirkstoff (Principe actif) |
|
PRC
|
- | Substance | WIZUS |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HBESI |
Reimbursement information
Public price
CHF 304.75
Specialties list
Yes
Generic
Yes
Reimbursement limitation
SL addition date:
01/10/2022
Authorization holder
Labatec Pharma SA
1217 Meyrin
Authorization information
- Swissmedic authorization number
- 68433
- Drug name
- Caspofungin Labatec, Poudre pour solution à diluer pour perfusion
- Galenic form
- PULPI
- ATC Code
- J02AX04
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 16/06/2022
- Authorization expiration date
- 15/06/2027
- IT number
- 08.06.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- CASPOFUNGIN Labatec subst sèche 50 mg flac
- Description (DE)
- CASPOFUNGIN Labatec Trockensub 50 mg Durchstf
- Market launch
- 16/06/2022
- Narcotic (BTM)
- No
Original drug
Cancidas, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
GTIN:
7680555840011
CHF 475.20